Jordan Engelhardt
Patterson Belknap Webb & Tyler LLP
Articles
Federal Circuit Upholds Jury Award, Weighs in on Willfulness Standard, in Adynovate® Dispute
USA - March 30 2021 According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s…
Sandoz Petitions the Supreme Court for Review of Enbrel® Patent License
USA - March 8 2021 The fight over proposed Enbrel® (etanercept) biosimilar Erelzi® continues. Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (“Sandoz”) recently…
FDA Approves Breyanzi®—A New Biologic for Treating Large B-Cell Lymphoma
USA - February 9 2021 On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed…
2021 Biosimilar Approval and Litigation Update
USA - February 1 2021 The last two years saw the launch of several biosimilars. Looking ahead to 2021, several others may be on the horizon. In 2019-2020, the FDA approved…
Rehearing Denied in Federal Circuit Hatch-Waxman Venue Case
USA - January 28 2021 The Federal Circuit has spoken. In a per curiam opinion, it denied Valeant’s petition for rehearing by the panel and rehearing en banc. A case…
